GenScript Appoints New Board Members to Drive Global Growth
PISCATAWAY, N.J., Sept. 12, 2024 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript"), a global leader in life sciences products and services, announced the appointment of Dr.Ross Allen Grossman as a Non-Executive Director and Dr.Alphonse Galdes as an Independent Non-Executive Director. Th...
GenScript Biotech Reports First Half 2024 Results
Strong Revenue Growth and Strategic Advances Across Key Segments, Enhances Commitment to ESG and Sustainable Development * Impressive Financial Growth: The group reported a 43.5% increase in revenue, driven by a 156% boost in cell therapy revenue and a 75.4% rise in gross profit, showcasing s...
GenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint
PISCATAWAY, N.J., April 24, 2024 /PRNewswire/ -- Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 Environmental, Social, and Governance (ESG) report. This report showcases the company's dedicated...
GenScript Biotech officially joins SBTi to fulfill its sustainability commitment
PISCATAWAY, N.J., April 15, 2024 /PRNewswire/ -- On April 15, GenScript Biotech Corporation ("GenScript"), a world's leading technology and service provider of life science R&D and manufacture, announced that it has joined The Science Based Targets initiative (SBTi) and submitted the Science Base...
GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%
R&D Innovation to Lead the Future, Deepening Customer Value Creation * Sustained High Revenue Growth: GenScript Group's five-year CAGR stands at an impressive 30%, with a strong global operation and stable cash flow. In 2023, the group's best-in-class cell therapy product CARVYKTI®, achieved sa...
San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry
SAN FRANCISCO, Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus toSan Francisco. The J.P. Morgan Healthcare Conference has been successfully held here for 42 editions, becoming a hall where industry thought converges and spar...
GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare Sector
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, will be attending the 42nd JPM Healthcare Conference held inSan Francisco, California, USA, from Ja...
GenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT Industry
NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On January 10, 2024, the GenScript Biotech Global Forum is set to inaugurate with grandeur during the 42nd J.P. Morgan Healthcare Conference inSan Francisco, USA. The forum, themed " Innovations and Breakthroughs Shaping Tomorrow's Cell and Gene Therapi...
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
NANJING, China, Dec. 24, 2023 /PRNewswire/ -- The innovative development of biopharmaceuticals has ushered in a new era for disease treatment, bringing unprecedented hope to countless patients. However, the transition from basic research to clinical commercialization presents formidable challenge...
CRISPR Continuous to Innovate! Exploring the Future of Cell & Gene Therapy, Industry Leaders Converge at the 2024 GenScript Biotech Global Forum
NANJING, China, Dec. 7, 2023 /PRNewswire/ -- The rapid advancement of technology has propelled the field of life sciences into unprecedented growth, constantly expanding our understanding and imagination. Particularly in the field of cellular gene therapy, a series of recent positive developments...
Genscript Biotech Reports 2022 Annual Results*
Non-Cell Therapy Achieved 31.4% Adjusted Net Profit Growth Cell Therapy Business Revenue Surged By 70% * Revenue of the Group for the year ended December 31, 2022 was approximately US$625.7 million, representing an increase of 27.7% as compared with approximatelyUS$490.1 million for the year e...
GenScript takes home Executive of the Year - Biotechnology at the SBR Management Excellence Awards 2022
Mr. Johnson Wang has propelled the GenScript APAC team to achieve numerous milestones despite external challenges. SINGAPORE, Nov. 18, 2022 /PRNewswire/ -- Global biotechnology corporation, GenScript Asia Pacific's President, Mr.Johnson Wang bagged the Executive of the Year - Biotechnology title...
GenScript Supported Nasal Spray Development for COVID-19 Protection with GMP-grade Antibodies and Subsequently Planned for Long-Term Collaboration with Biogenexis
SINGAPORE, Nov. 1, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a leading global biotechnology company supportedChulalongkorn University, a research-intensive university in Thailand in developing human anti-SARS-CoV-2 antibodies with antibody production a...
GenScript ProBio Enters Strategic Collaboration with Hibiocy Co. Ltd, the affiliate of Rojukiss International Public Company Limited (KISS) - the leading Thai-based Beauty & Health company, for the development and manufacturing of COVITRAP™ and future new products.
SINGAPORE, Oct. 17, 2022 /PRNewswire/ -- GenScript ProBio (a global one-stop CDMO from GenScript Group) today announced a strategic collaboration with Hibiocy Co. Ltd., a private corporation based inBangkok, Thailand, to accelerate a respiratory-care medical device, COVITRAP™ which contains human...
GenScript Receives Best Cell & Gene Therapy Supplier Award: Gene Editing and GenScript ProBio Receives Best Biologics CMO Awards: Upstream Processing & Analytical Services
SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) and GenScriptProBio (a global one-stop CDMO from GenScript Group) receive 3 awards: Best Cell & Gene Therapy Supplier Award – Gene Editing on the Asia-Pacific Cell & Gene Therapy Excellence ...
GenScript Biotech Collaborates with Singapore Institute of Technology on Talent Development and Applied Research Projects
Singapore, May 26, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) and the Singapore Institute of Technology (SIT) signed a Memorandum of Understanding (MoU) today to develop Continuing Education and Training (CET), work-study degree programmes and explore ap...
GenScript Receives "Best Contract Development and Manufacturing Organization Award" For the Third Time in a Row
SINGAPORE, March 30, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) receives the "Best Contract Development and Manufacturing Organization Award" on the Asia Pacific Bioprocessing Excellence Awards 2022. This marks the third consecutive year of GenScript bag...
GenScript Sets Up State-Of-Art Manufacturing Facility in Singapore to Strengthen Manufacturing Capability
SINGAPORE, Feb. 10, 2022 /PRNewswire/ -- GenScript Biotech Corporation (Stock Code: 1548.HK), the world's leading life science research tools and services provider, today announced the opening of more than 30,000-square-feet facility for highly automated protein and gene preparation services. The...
GenScript Receives "COVID Management Initiative of the Year" in Singapore Business Review Management Excellence Award 2021
SINGAPORE, Dec. 15, 2021 /PRNewswire/ -- GenScript receives the award on COVID Management Initiative of the Year, Biotechnology industry in the Singapore Business Review (SBR) Management Excellence Award 2021. GenScript showed strong commitment and support to global COVID-19 management including ...
GenScript and BioComo Join Forces to Accelerate Novel Intranasal SARS-CoV-2 Vaccine Development in Japan
TOKYO and SINGAPORE, Dec. 1, 2021 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a leading global biotechnology company, and BioComo Incorporation, a drug discovery venture based in Mie prefecture,Japan, today announces a strategic agreement for joint research a...